Pegcetacoplan Effective in Real-World Setting for CI-Naive, CI-Experienced PNH Patients Researchers compared the response to pegcetacoplan therapy at treatment initiation and at the time of surveying CI-experienced vs CI-naive patients.

Treatment with #Pegcetacoplan has demonstrated significant improvements in hematologic parameters in both #ComplementInhibitor (CI)-experienced and CI-naive patients with #PNH in real-world clinical settings across Europe and Canada.

Learn more: https://bit.ly/4a12G9s

Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN | NEJM C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis (MPGN) generally result in glomerular C3 deposition and irreversible kidney damage. The efficacy and safety of ...

Proud of Manchester’s paediatric participation in this game-changing trial published this week in @nejm.org
A golden dawn in renal rare disease
#C3G #IC-MPGN #pegcetacoplan #complement

www.nejm.org/doi/full/10....

Positive Outcomes from VALIANT Phase 3 Study Published in NEJM Highlight Pegcetacoplan's Efficacy for Kidney Diseases The VALIANT Phase 3 study reveals pegcetacoplan's effectiveness for C3 glomerulopathy and primary IC-MPGN, showcasing meaningful clinical benefits.

Positive Outcomes from VALIANT Phase 3 Study Published in NEJM Highlight Pegcetacoplan's Efficacy for Kidney Diseases #Sweden #Stockholm #C3G #pegcetacoplan #IC-MPGN

Sobi to Showcase New Insights on pegcetacoplan at ASN Kidney Week 2025 Sobi will present compelling new data on the efficacy of pegcetacoplan for C3G and primary IC-MPGN during ASN Kidney Week 2025 in Houston, Texas.

Sobi to Showcase New Insights on pegcetacoplan at ASN Kidney Week 2025 #United_States #Houston #Sobi #ASN_Kidney_Week #pegcetacoplan

Pegcetacoplan Shows Positive Results for Adolescents With C3G and IC-MPGN | Docwire News Pegcetacoplan was found to reduce proteinuria and stabilize eGFR in adolescent patients with C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis.

Pegcetacoplan reduced proteinuria and stabilized eGFR in adolescent patients with C3G or primary IC-MPGN. #kidneydisease #c3g #icmpgn #pediatrics #nephrology #nephsky #pegcetacoplan www.docwirenews.com/post/pegceta...

Pegcetacoplan Benefits Patients With C3G/IC-MPGN and Nephrotic Proteinuria | Docwire News An analysis confirmed the efficacy and safety of pegcetacoplan for patients with C3 glomerulopathy and primary immune complex membranoproliferative and nephrotic range proteinuria.

An analysis confirmed the efficacy and safety of #pegcetacoplan for patients with C3G/IC-MPGN and nephrotic range #proteinuria. #C3G #ICMPGN #kidneydisease #nephrology #nephsky www.docwirenews.com/post/pegceta...

The June issue is out now! Highlights include a feature on the role of #ChiefWellnessOfficers, a clinical case with profound #thrombocytopenia and findings suggestive of an MPN, #pegcetacoplan for pediatric PNH, and more. Check out the full lineup here: ow.ly/wRT150W2Yf7
#HemeSky #HemeOnc